; and (2) drug-gene and drug-drug-gene associations, established by a drug product’s label or peer-reviewed professional guidelines, based on a patient’s medication list, medication allergy list, and results from pharmacogenomic testing. (b) Guidance on drug-Gene interaction alerting systems (1) Issuance and updates The Secretary shall— (A) issue routine guidance on drug-gene interaction alerting systems in electronic health records; and (B) not less than biannually, update such guidance to incorporate pharmacogenomic information from— (i) new or updated drug labels; and (ii) newly established peer-reviewed professional guidelines on drug-gene associations. (2) Rule of construction Nothing in paragraph (1) shall be construed as prohibiting an entity from updating the results of pharmacogenomic testing, or alerting the provider, if a medication is contraindicated by the results of pharmacogenomic testing. (c) Reducing adverse drug events reporting burdens The Secretary shall encourage the development of electronic health record systems that allow for adverse drug event information to be directly reported to the FDA Adverse Event Reporting System. (d) Updating FAERS; patient-Friendly reporting The Secretary shall— (1) update the FDA Adverse Event Reporting System, including to— (A) create an optional selection tool that allows individuals to report whether an adverse drug event is associated with a drug-gene or drug-drug-gene interaction; and (B) accept information directly from health care providers’ electronic health record systems; (2) work with relevant Federal agencies and offices, and stakeholders, to create patient-friendly electronic options for reporting adverse drug events such as submission through an optional designated mobile device application or mobile device messaging application